Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects
This study has been completed.
First Posted: February 11, 2009
Last Update Posted: December 1, 2016
Information provided by (Responsible Party):
Novartis ( Novartis Vaccines )